blog

Dr. Oluwatosin Smith Advocates Early Glaucoma Care at ASCRS 2025 At the prestigious American Society of Cataract and Refractive Surgery (ASCRS) 2025 conference, renowned ophthalmologist Dr. Oluwatosin Smith delivered a compelling keynote address on the critical importance of early glaucoma detection and intervention. With glaucoma being a leading cause of irreversible blindness worldwide, Dr. Smith’s […]

Enhanced IOP Control with Anti-VEGF and MMC Surgical Therapy Managing intraocular pressure (IOP) is a critical aspect of treating glaucoma and other ocular conditions that threaten vision. Traditional surgical interventions, while effective, often come with complications such as scarring and inflammation. However, combining anti-VEGF (vascular endothelial growth factor) therapy with mitomycin C (MMC) surgical therapy

Preventable Glaucoma Vision Loss Hindered by Treatment Costs Glaucoma, often called the “silent thief of sight,” is a leading cause of irreversible blindness worldwide. Shockingly, much of the vision loss caused by this condition is preventable—if detected early and treated properly. However, a major barrier stands in the way: the high cost of treatment. Many

Optic Nerve Hemoglobin Levels Impact Glaucoma Structure and Function Glaucoma is a leading cause of irreversible blindness worldwide, characterized by progressive damage to the optic nerve and retinal ganglion cells. While elevated intraocular pressure (IOP) has long been recognized as a major risk factor, emerging research suggests that optic nerve hemoglobin levels may play a

Innovative Minimally Invasive Glaucoma Treatments in Development Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. Traditional treatments, such as eye drops, laser therapy, and invasive surgeries, have been the mainstay for managing intraocular pressure (IOP). However, these methods often come with limitations, including side effects, compliance issues, and variable efficacy.

Understanding Age-Related Glaucoma Progression: Key Insights Glaucoma is a leading cause of irreversible blindness worldwide, particularly affecting older adults. As we age, the risk of developing glaucoma increases, making it crucial to understand how this condition progresses over time. Early detection and proper management can help preserve vision and improve quality of life. In this

Surge in Three Major Eye Diseases Linked to Blindness In recent years, the prevalence of eye diseases leading to blindness has seen a concerning rise. With aging populations, increased screen time, and environmental factors, experts warn that conditions like glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are becoming more widespread. Understanding these diseases, their

PreserFlo MicroShunt Complications Lead to Corneal Damage and Surgical Revision The PreserFlo MicroShunt has been widely adopted as a minimally invasive surgical option for glaucoma patients, offering an alternative to traditional trabeculectomy. While the device has shown promise in reducing intraocular pressure (IOP), emerging reports highlight complications such as corneal damage and the need for

National Reconstruction Fund Invests $27M in Glaucoma Treatment Innovation The National Reconstruction Fund (NRF) has announced a groundbreaking investment of $27 million into cutting-edge glaucoma treatment innovation. This significant funding aims to accelerate research, development, and commercialization of advanced therapies to combat glaucoma—a leading cause of irreversible blindness worldwide. The move underscores the government’s commitment

Brandon Capital and Labor’s NRF Invest $40M in Glaucoma Biotech PolyActiva The biotechnology sector continues to attract significant investment as innovative companies push the boundaries of medical science. In a major development, Brandon Capital and Labor’s National Reconstruction Fund (NRF) have jointly invested $40 million in PolyActiva, an Australian biotech firm specializing in glaucoma treatments.